BetaVia has received approval as a novel ingredient in Brazil
Kemin Industries, a global ingredient manufacturer, has announced that its human nutrition and health product for immune support, BetaVia, has received approval as a novel ingredient in Brazil.
On November 9, the Health Regulatory Agency (Anvisa) of the Brazilian Ministry of Health published a resolution authorising BetaVia for use as a new food ingredient in the country.
This authorisation in Brazil follows a recent positive safety evaluation conducted by the European Food Safety Authority (EFSA) on BetaVia, as well as BetaVi's Generally Recognized as Safe (GRAS) self-affirmed status from the US FDA.
"We are extremely excited to learn of Anvis's approval of BetaVia, as Brazil is a key strategic market in terms of growth for the product and Kemin Human Nutrition and Health," said José Piccolotto, President of Kemin Human Nutrition and Health. "Brazil is one of many countries showing a desire to provide immune-enhancing ingredients in its functional food and beverages and dietary supplements, and our ingredients - including BetaVia - meet this need."
BetaVia is manufactured through a patented fermentation process using a proprietary strain of the algae Euglena gracilis. The finished product offers beneficial immunomodulatory effects that are supported by clinical and preclinical research.
A recently published clinical trial showed that participants who received a supplement containing BetaVia Complete for a 90-day period experienced the following immune-health benefits when compared to those participants who received a placebo:
"Kemin is focused on delivering high-quality, sustainable solutions to our customers, and we look forward to meeting the growing immune health needs within the Brazilian market," said Rosemeire Shiraishi, Sales Manager for Latin America at Kemin Human Nutrition and Health.